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We conducted a retrospective study to clarify the clinical significance of metastasectomy in patients with
metastatic renal cell carcinoma (mRCC). Of 83 mRCC patients who were treated at our hospital between
2005 and 2010, 19 patients who underwent metastasectomy during the treatment course were the subjects of
the present study. By the purpose and timing of metastasectomy, we classified the 19 patients into three
groups : (1) patients who immediately underwent metastasectomy at diagnosis of metastasis (primary group),
(2) patients who underwent resection of clinically problematic metastatic lesions for the relief of their
symptoms (palliative group), and (3) patients who underwent complete resection of all metastatic lesions after
sufficient systemic therapies (consolidation group). In the primary group (n＝5), four patients had lung
metastasis and one had metastases to limbs and the adrenal gland. Overall survival at 3 years was 100%.
In the palliative group (n＝4), 3 patients underwent resection of brain metastasis and one underwent resec-
tion of skin metastasis. The symptoms associated with metastasis clearly improved. In the consolidation
group (n＝10), the metastasized organ was the lung in 5 patients, pancreas in 4, and liver in one. Preope-
rative systemic therapy included sunitinib or sorafenib in 5 patients, interferon-α in 4, and S-1 in one. After
metastasectomy, systemic therapies were discontinued in 9 patients, 4 of whom did not experience RCC
recurrence, with a median follow-up of 35 months. Overall survival at 3 years was 60%. Metastasectomy
would be a good treatment option in patients with mRCC.
(Hinyokika Kiyo 61 : 49-54, 2015)



















































































































































































































































































































































































































腫瘍の進展度については Union for International Cancer
Control (UICC) による TNM 悪性腫瘍の分類改訂第
7 版（2009年）7)に基づき記載した．一般全身状態
(PS) の評価については Eastern Clinical Oncology
Group (ECOG)-PS を用い評価した．全身治療の治療
効果は，固形がんの治療効果判定のための新ガイドラ
イン (RECIST version 1.1）8)を用いて評価した．生
存期間については，転移巣切除術施行日を起算日とし
全生存期間，無再発生存期間を算出し， 2群間の比較






であった．切除臓器は，肺 9例，膵臓 4例，脳 3例，






は，インターフェロン (IFN)-α 5例，sunitinib 3例，






これら 19例は手術目的別に primary 群 5 例，
palliative 群 4例，consolidation 群10例に分類された．
Primary 群 5例中 4例は肺転移に，また 1例は副腎転
移とともに肋骨転移を対象に転移巣切除術が行われた
(Table 1）．肺転移の 4例は術後全身治療を行わず経
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Consolidation 群10例中， 5例は肺転移， 4例は膵臓
転移， 1例は肝臓転移であった (Table 3）．転移巣切
除術直前の治療薬は，インターフェロン (IFN)-α 4
例，sunitinib 2 例，sorafenib 2 例，axitinib 1 例，S-1
1 例であった．術直前の治療効果判定は PR 3 例，
SD 2例，PD 5例であった．PD の 5例は全例測定可
能病変の増大によるもので，新規病変を有したものは
なかった．手術直前の ECOG-PS は，PS0 が 6 例，





（肺転移 4例，膵転移 4例，肝転移 1例）で転移巣切
除後全身治療を中止したが， 5例で再発を認めた．肺
転移例では 2例が肺再発，膵転移例では 1例が肝， 1
例が耳下腺，肝転移例では対側腎であった．再発後治
療は転移巣切除 3例，temsirolimus 投与 1例，経過観
察 1 例であった．転移巣切除術後の 3 年全生存率は
60％（95％CI 24∼96％）であった (Fig. 1）．術前治療
効果判定別の検討で 3 年全生存率は PR＋SD 群で
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